Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to describe how women with BRCA1/2 mutations react to genetic risk modifier testing, and to examine how they make decisions about their healthcare.
Eligibility
- Age range
- 25+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: Phase I: * Female patient, age 25 years or older (given that women under this age are not generally recommended to receive BRCA1/2 genetic testing) * Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified * No personal history of breast cancer * English-fluent; the surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, pa…
Interventions
- OtherSalvia sample
salvia sample
- BehavioralQuestionnaires
Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
- OtherBuccal swab sample
Buccal swab sample
Locations (7)
- Dana Farber Cancer Institute (Data Collection Only)Boston, Massachusetts
- Memorial Sloan-Kettering at Basking RidgeBasking Ridge, New Jersey
- Memorial Sloan Kettering CommackCommack, New York
- Memorial Sloan Kettering WestchesterHarrison, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Memorial Sloan Kettering NassauUniondale, New York